Genome-wide association studies in pharmacogenomics: successes and lessons.
Genome-wide association studies in pharmacogenomics: successes and lessons.
复制标题
DOI：
10.1097/fpc.0b013e32833d7b45
复制
发表时间：
2013-08
影响因子：
2.6
通讯作者：
Roden DM
中科院分区：
文献类型：
--
作者：
Motsinger-Reif AA;Jorgenson E;Relling MV;Kroetz DL;Weinshilboum R;Cox NJ;Roden DM
随着基因分型技术的发展，全基因组关联研究（GWAS）已成熟成绘制人类表型基因基因的高效工具。最近的研究表明，GWAS方法用于检查药物基因组学性状，包括药物代谢，疗效和毒性。 GWA在药物基因组成果上的应用带来了独特的挑战和机遇。在当前的综述中，我们特别讨论了这种方法的潜在承诺和潜在的警告，因为它与药物基因组学研究有关。审查了研究设计，功率和样本量以及分析的关注。我们进一步研究了成功的药物基因组GWAS的特征，并描述了财团的工作，这些康复可能会在未来扩大药物基因组GWA的覆盖范围。
As genotyping technology has progressed, genome-wide association studies (GWAS) have matured into efficient and effective tools for mapping genes underlying human phenotypes. Recent studies have demonstrated the utility of the GWAS approach for examining pharmacogenomic traits, including drug metabolism, efficacy, and toxicity. Application of GWAS to pharmacogenomic outcomes presents unique challenges and opportunities. In the current review, we discuss the potential promises and potential caveats of this approach specifically as it relates to pharmacogenomic studies. Concerns with study design, power and sample size, and analysis are reviewed. We further examine the features of successful pharmacogenomic GWAS, and describe consortia efforts that are likely to expand the reach of pharmacogenomic GWAS in the future.